Prognostic Significance of New Immunohistochemical Markers in Refractory Classical Hodgkin Lymphoma: A Study of 59 Cases

PLoS ONE - United States
doi 10.1371/journal.pone.0006341
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Public Library of Science (PLoS)

Related search

Prognostic Value of Immunohistochemical Markers in Stage Iii/Iv Classical Hodgkin Lymphoma Treated Frontline in the Lysa Eortc 20012 Randomized Protocol

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Prognostic Significance of Immunohistochemical Markers in Glioma Patients

2011English

Prognostic Significance of Tryptophan Catabolism in Newly Diagnosed Hodgkin Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Evita: Phase I/Ii Study of Everolimus Plus Itacitinib in Relapsed/Refractory Classical Hodgkin Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Treatment of Relapsed and Refractory Hodgkin Lymphoma – Recommendations of the Czech Hodgkin Lymphoma Study Group

Klinicka Onkologie
Oncology
2016English

Combination of Nivolumab and Bendamustine in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Lymphocyte-Rich Classical Hodgkin Lymphoma

Atlas of Genetics and Cytogenetics in Oncology and Haematology
Cancer ResearchOncologyGeneticsHematology
2018English

Circulating Dendritic Cells Deficiencies as a New Biomarker in Classical Hodgkin Lymphoma

British Journal of Haematology
Hematology
2018English

Suppressor of Cytokine Signaling 1 Gene Mutation Status as a Prognostic Biomarker in Classical Hodgkin Lymphoma

Oncotarget
Oncology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy